SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-20-019714
Filing Date
2020-04-29
Accepted
2020-04-29 16:15:25
Documents
4
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A sbph-defa14a_20200429.htm DEFA14A 31754
2 GRAPHIC gapn2bgo3w1b000003.jpg GRAPHIC 16702
3 GRAPHIC gapn2bgo3w1b000002.jpg GRAPHIC 60680
4 GRAPHIC gapn2bgo3w1b000001.jpg GRAPHIC 35982
  Complete submission text file 0001564590-20-019714.txt   189350
Mailing Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748
Business Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748 508-473-5993 X119
Spring Bank Pharmaceuticals, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37718 | Film No.: 20830492
SIC: 2834 Pharmaceutical Preparations